About Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Sector: Biotechnology & Medical Research - NEC
- Symbol: NYSEAMERICAN:PLX
- Previous Symbol: NYSEMKT:PLX
- CUSIP: N/A
- Web: www.protalix.com
- Outstanding Shares: 139,730,000
Frequently Asked Questions for Protalix Biotherapeutics (NYSEAMERICAN:PLX)
What is Protalix Biotherapeutics' stock symbol?
Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."
How were Protalix Biotherapeutics' earnings last quarter?
Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) posted its earnings results on Wednesday, November, 8th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.04. The firm had revenue of $7.53 million for the quarter, compared to analysts' expectations of $6.65 million. During the same period last year, the firm earned ($0.07) EPS. View Protalix Biotherapeutics' Earnings History.
Where is Protalix Biotherapeutics' stock going? Where will Protalix Biotherapeutics' stock price be in 2017?
3 brokerages have issued 12 month target prices for Protalix Biotherapeutics' stock. Their predictions range from $1.00 to $5.00. On average, they expect Protalix Biotherapeutics' share price to reach $3.67 in the next twelve months. View Analyst Ratings for Protalix Biotherapeutics.
Are investors shorting Protalix Biotherapeutics?
Protalix Biotherapeutics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 6,749,650 shares, an increase of 1.6% from the October 13th total of 6,642,728 shares. Based on an average daily volume of 3,511,610 shares, the days-to-cover ratio is presently 1.9 days. Approximately 5.5% of the company's shares are short sold.
Who are some of Protalix Biotherapeutics' key competitors?
Some companies that are related to Protalix Biotherapeutics include TG Therapeutics (TGTX), Voyager Therapeutics (VYGR), Horizon Discovery Group PLC (HZD), Puretech Health PLC (PRTC), Cellular Dynamics International (ICEL), Zynerba Pharmaceuticals (ZYNE), Palatin Technologies (PTN), Silence Therapeutics plc (SLN), Asterias Biotherapeutics (AST), Matinas BioPharma Holdings (MTNB), NovaBay Pharmaceuticals (NBY), Navidea Biopharmaceuticals (NAVB), Tissue Regenix Group PLC (TRX), ReNeuron Group Plc (RENE), Abzena PLC (ABZA), Scancell Holdings Plc (SCLP), Can Fite Biopharma Ltd (CANF) and Oxford Pharmascience Group Plc (OXP).
Who are Protalix Biotherapeutics' key executives?
Protalix Biotherapeutics' management team includes the folowing people:
- Shlomo Yanai, Chairman of the Board (Age 64)
- Moshe Manor, President, Chief Executive Officer, Director (Age 60)
- Yossi Maimon CPA, Chief Financial Officer, Vice President, Treasurer, Secretary (Age 46)
- Tzvi Palash, Chief Operating Officer (Age 60)
- Yoseph Shaaltiel Ph.D., Executive Vice President - Research & Development (Age 63)
- Einat Brill Almon Ph.D., Senior Vice President - Product Development (Age 57)
- Amos Bar-Shalev, Independent Director (Age 64)
- Zeev Bronfeld, Independent Director (Age 66)
- Yodfat Harel Buchris, Independent Director (Age 45)
- Roger D. Kornberg Ph.D., Independent Director (Age 69)
How do I buy Protalix Biotherapeutics stock?
Shares of Protalix Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protalix Biotherapeutics' stock price today?
One share of Protalix Biotherapeutics stock can currently be purchased for approximately $0.67.
How big of a company is Protalix Biotherapeutics?
Protalix Biotherapeutics has a market capitalization of $333.79 million.
How can I contact Protalix Biotherapeutics?
Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.
MarketBeat Community Rating for Protalix Biotherapeutics (NYSEAMERICAN PLX)MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Protalix Biotherapeutics (NYSEAMERICAN:PLX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$3.67|
Consensus Price Target History for Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Analysts' Ratings History for Protalix Biotherapeutics (NYSEAMERICAN:PLX)
(Data available from 11/19/2015 forward)
|11/9/2017||HC Wainwright||Reiterated Rating||Buy||$5.00|
|5/23/2017||Rodman & Renshaw||Reiterated Rating||Buy||$5.00|
|9/6/2016||Jefferies Group LLC||Lower Price Target||Buy||$1.75 -> $0.80|
Earnings History and Estimates Chart for Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Earnings History by Quarter for Protalix Biotherapeutics (NYSEAMERICAN PLX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q3 17||($0.05)||($0.09)||$6.65 million||$7.53 million||View||N/A|
|8/9/2017||6/30/2017||($0.04)||($0.06)||$5.05 million||$6.36 million||View||Listen|
|5/10/2017||Q1 17||($0.09)||($0.07)||$2.55 million||$2.89 million||View||N/A|
|8/8/2016||Q2 16||($0.08)||($0.11)||$1.34 million||$1.77 million||View||N/A|
|3/8/2016||Q415||($0.29)||$3.50 million||$4.40 million||View||N/A|
|11/9/2015||Q3 15||($0.08)||($0.04)||$5.00 million||$4.30 million||View||N/A|
|8/10/2015||Q215||($0.08)||($0.05)||$6.40 million||$3.78 million||View||N/A|
|5/7/2015||Q1 15||($0.08)||($0.06)||$8.20 million||$4.39 million||View||N/A|
|8/7/2014||($0.07)||($0.07)||$9.63 million||$2.43 million||View||N/A|
|5/8/2014||($0.07)||($0.08)||$8.25 million||$6.70 million||View||N/A|
|3/13/2014||Q413||($0.02)||($0.12)||$5.54 million||$2.36 million||View||N/A|
Earnings Estimates for Protalix Biotherapeutics (NYSEAMERICAN:PLX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Protalix Biotherapeutics (NYSEAMERICAN:PLX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Protalix Biotherapeutics (NYSEAMERICAN PLX)
Insider Trades by Quarter for Protalix Biotherapeutics (NYSEAMERICAN PLX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/2/2017||Randall Peel Boyd||Insider||Buy||38,300||$0.47||$18,001.00|
|5/16/2017||Moshe Manor||CEO||Buy||50,000||$0.81||$40,500.00|| |
|1/27/2017||Terence Stanley Meek||Director||Buy||12,000||$0.42||$5,040.00|
|1/25/2017||Madalena Energy Inc.||Insider||Sell||190,500||$0.38||$72,390.00|
|1/23/2017||Madalena Energy Inc.||Insider||Sell||500||$0.39||$195.00|
|1/12/2017||Madalena Energy Inc.||Insider||Sell||54,000||$0.42||$22,680.00|
|1/11/2017||Madalena Energy Inc.||Insider||Sell||51,000||$0.44||$22,440.00|
|12/2/2016||Camber Capital Management Llc||Major Shareholder||Sell||2,500,000||$0.32||$800,000.00|| |
|12/14/2015||Yossi Maimon||CFO||Buy||10,000||$0.78||$7,800.00|| |
|10/19/2015||Camber Capital Management Llc||Major Shareholder||Buy||4,000,423||$1.00||$4,000,423.00|| |
|8/15/2013||Alfred Akirov||Director||Sell||112,330||$5.05||$567,266.50|| |
Latest Headlines for Protalix Biotherapeutics (NYSEAMERICAN PLX)
Protalix Biotherapeutics (NYSEAMERICAN PLX) Chart for Sunday, November, 19, 2017